Liquidia settles all pending litigation with United Therapeutics, agrees to USD 380.7 million net payment
Liquidia entered a global settlement with United Therapeutics that ends all pending litigation between the companies. Deal follows a Sept. 30, 2026 Delaware court ruling that two claims of United Therapeutics’ ’327 patent were valid and infringed. Liquidia agreed not to appeal. It filed a label supplement removing the